Gaining ligand selectivity in thyroid hormone receptors via entropy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 49, 2009, Pages 20717-20722

  Martínez, Leandro ^a   Nascimento, Alessandro S ^b   Nunes, Fabio M ^b   Phillips, Kevin ^c   Aparicio, Ricardo ^a,b   Dias, Sandra Martha G ^b,e   Figueira, Ana Carolina M ^b   Lin, Jean H ^c   Nguyen, Phuong ^c   Apriletti, James W ^c   Neves, Francisco A R ^d   Baxter, John D ^c   Webb, Paul ^c   Skaf, Munir S ^a   Polikarpov, Igor ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF BRASILIA   (Brazil)

^e Department of Obstetrics Gynecology   (United States)

Author keywords

Design; Mobility; Triac

Indexed keywords

CARBOXYLIC ACID; CELL NUCLEUS RECEPTOR; THYROID HORMONE RECEPTOR; TIRATRICOL;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; ENTROPY; HUMAN; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

ACETIC ACID; BINDING SITES; ENTROPY; HUMANS; HYDROGEN BONDING; LIGANDS; MOLECULAR DYNAMICS SIMULATION; PLIABILITY; STATIC ELECTRICITY; THERMODYNAMICS; THYROID HORMONE RECEPTORS ALPHA; THYROID HORMONE RECEPTORS BETA; TRIIODOTHYRONINE; WATER;

EID: 73949144655     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0911024106     Document Type: Article

References (40)

1. Baxter JD, et al. (2001) Selective modulation of thyroid hormone receptor action. J Steroid Biochem Mol Biol 76:31-42.
2. Laudet V, Gronemeyer H (2002) The Nuclear Receptor Facts Book (Academic, London).
3. Yen PM (2001) Physiological and molecular basis of thyroid hormone action. Physiol Rev 81:1097-1142.
4. Baxter JD, Webb P (2009) Thyroid hormone mimetics: Potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 8:308-320.
5. Berkenstam A, et al. (2008) The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 105:663-667.
6. Wagner RL, et al. (1995)Astructural role for hormone in the thyroid hormone receptor. Nature 378:690-697.
7. Wagner RL, et al. (2001) Hormone selectivity in thyroid hormone receptors. Mol Endocrinol 15:398-410.
8. Ye L, et al. (2003) Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor β1. J Med Chem 46:1580-1588.
9. Bleicher L, et al. (2008) Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms. BMC Struct Biol 8:8.
10. Borngraeber S, et al. (2003) Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc Natl Acad Sci USA 100:15358-15363.
11. Schueler PA, Schwartz HL, Strait KA, Mariash CN, Oppenheimer JH (1990) Binding of 3,5,3′-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: Differences in the affinity of the α- and β-forms for the acetic acid analog and failure of the human testis and kidney α-2 products to bind T3. Mol Endocrinol 4:227-234.
12. Karplus M, McCammon JA (2002) Molecular dynamics simulations of biomolecules. Nat Struct Biol 9:646-652.
13. Martinez L, et al. (2005) Molecular dynamics simulations reveal multiple pathways of ligand dissociation from thyroid hormone receptors. Biophys J 89:2011-2023.
14. Martinez L, Webb P, Polikarpov I, Skaf MS (2006) Molecular dynamics simulations of ligand dissociation from thyroid hormone receptors: Evidence of the likeliest escape pathway and its implications for the design of novel ligands. J Med Chem 49:23-26.
15. Martinez L, Polikarpov I, Skaf MS (2008) Only subtle protein conformational adaptations are required for ligand binding to thyroid hormone receptors: Simulations using a novel multipoint steered molecular dynamics approach. J Phys Chem B 112:10741-10751.
16. Xiang Z, Soto CS, Honig B (2002) Evaluating conformational free energies: The colony energy and its application to the problem of loop prediction. Proc Natl Acad Sci USA 99:7432-7437.
17. Sherman SI, et al. (1997) Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. J Clin Endocr Metab 82:2153-2158.
18. Ladbury JE (1996) Just add water! The effect of water on the specificity of protein-ligand binding sites and its potential application to drug design. Chem Biol 3:973-980.
19. Holdgate GA, et al. (1997) The entropic penalty of ordered water accounts for weaker binding of the antibiotic novobiocin to a resistant mutant of DNA gyrase: A thermodynamic and crystallography study. Biochemistry 36:9663-9673.
20. Velazquez-Campoy A, et al. (2000) Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor. Protein Sci 9:1801-1809.
21. Kavanagh KL, et al. (2006) The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 103:7829-7834.
22. Sheu SY (2006) Selectivity principle of the ligand escape process from a two-gate tunnel in myoglobin: Molecular dynamics simulation. J Chem Phys 124:154711.
23. Bastug T, Gray-Weale A, Patra SM, Kuyucak S (2006) Role of protein flexibility in ion permeation: A case study in gramicidin. Biophys J 90:2285-2296.
24. Hourai S, et al. (2006) Probing a water channel near the A-ring of receptor-bound 1α,25-dihydroxyvitamin D3 with selected 2α-substituted analogues. J Med Chem 49:5199-5205.
25. Vaisanen S, Perakyla M, Karkkainen JI, Uskokovic MR, Carlberg C (2003) Structural evaluation of the agonistic action of a vitamin D analog with two side chains binding to the nuclear vitamin D receptor. Mol Pharmacol 63:1230-1237.
26. Molnar F, Perakyla M, Carlberg C (2006) Vitamin D receptor agonists specifically modulate the volume of the ligand-binding pocket. J Biol Chem 281:10516-10526.
27. Carlberg C, Molnar F (2006) Detailed molecular understanding of agonistic and antagonistic vitamin D receptor ligands. Curr Top Med Chem 6:1243-1253.
28. Kosztin D, Izrailev S, Schulten K (1999) Unbinding of retinoic acid from its receptor studied by steered molecular dynamics. Biophys J 76:188-197.
29. Sun J, et al. (1999) Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-α or estrogen receptor-β. Endocrinology 140:800-804.
30. Shiau AK, et al. (2002) Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 9:359-364.
31. Sandler B, et al. (2004) Thyroxine-thyroid hormone receptor interactions. J Biol Chem 279:55801-55808.
32. Waldron TT, Murphy KP (2003) Stabilization of proteins by ligand binding: Application to drug screening and determination of unfolding energetics. Biochemistry 42:5058-5064.
33. Freire E (2008)Doenthalpy and entropy distinguish first in class from best in class? Drug Disc Today 13:869-874.
34. Nascimento AS, et al. (2006) Structural rearrangements in the thyroid hormone receptor hinge domain and their putative role in the receptor function. J Mol Biol 360:586-598.
35. Togashi M, Nguyen P, Fletterick R, Baxter JD, Webb P (2005) Rearrangements in thyroid hormone receptor charge clusters that stabilize bound 3,5′,5-triiodo-L-thyronine and inhibit homodimer formation. J Biol Chem 280:25665-25673.
36. Martinez L, Andrade R, Birgin EG, Martinez JM (2009) PACKMOL: A package for building initial configurations for molecular dynamics simulations. J Comput Chem 30:2157-2164.
37. Phillips JC, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26:1781-1802.
38. MacKerell AD, et al. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102:3586-3616.
39. Kleywegt GJ, Jones TA (1994) Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallogr D 50:178-185.
40. Delano WL (2002) The PYMOL Molecular Graphics System (Delano Scientific, Palto Alto, CA).